ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

FDMT 4D Molecular Therapeutics Inc

24,90
0,00 (0,00%)
Pré-mercado
Última atualização: 05:00:00
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
4D Molecular Therapeutics Inc FDMT NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
0,00 0,00% 24,90 05:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
24,90
mais cotações »

Notícias Recentes

Data Hora Fonte Título
09/05/202417:05GLOBE4DMT Reports First Quarter 2024 Financial Results and..
07/05/202409:00GLOBE4DMT to Participate in Upcoming Investor Conference
01/05/202409:00GLOBE4DMT Announces Presentations at ARVO 2024 Annual Meeting
28/03/202409:00GLOBE4DMT Announces Update on Regulatory Interactions and..
04/03/202410:00GLOBE4DMT to Participate in Upcoming Investor Conferences
29/02/202418:05GLOBE4DMT Reports Full Year 2023 Financial Results and..
12/02/202410:00GLOBE4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2..
07/02/202401:27GLOBE4D Molecular Therapeutics Announces Pricing of Upsized..
05/02/202418:05GLOBE4D Molecular Therapeutics Announces Proposed Public Offering..
03/02/202419:00GLOBE4DMT Presents Positive Interim Data from Randomized Phase 2..
29/01/202410:00GLOBE4DMT to Host Corporate Webcast to Discuss Interim Data from..
23/01/202410:00GLOBE4DMT Receives Rare Pediatric Disease Designation from FDA..
04/01/202410:00GLOBE4DMT Highlights Recent Clinical Pipeline Progress, Near-Term..
03/01/202410:01GLOBE4DMT and Arbor Biotechnologies Establish Partnership to..
21/12/202314:31DJN4D Molecular Shares Rise on FDA Designation for Wet AMD Drug
21/12/202310:00GLOBE4DMT Receives FDA Regenerative Medicine Advanced Therapy..
04/12/202310:00GLOBE4DMT to Present Interim 24 Week Data from Randomized Phase 2..
15/11/202310:00GLOBE4DMT to Participate in Upcoming Investor Conferences
09/11/202318:19GLOBE4DMT Reports Third Quarter 2023 Financial Results and..
01/11/202317:00GLOBE4DMT Presents Positive Interim Data from Phase 1/2 AEROW..
30/10/202309:00GLOBE4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold..
25/10/202309:00GLOBE4DMT to Present Interim Data from Aerosolized 4D-710 Phase..
23/10/202309:00GLOBE4DMT Receives EMA Priority Medicines (PRIME) Designation for..
12/09/202317:05GLOBE4DMT Appoints Uneek Mehra as Chief Financial and Business..
07/09/202317:05GLOBE4DMT to Participate in Upcoming Investor Conferences
07/09/202309:00GLOBE4DMT Announces First Patient Enrolled in 4D-150 Phase 2..
09/08/202317:05GLOBE4D Molecular Therapeutics Reports Second Quarter 2023..
29/07/202313:00GLOBE4DMT Presents Additional Positive Interim Data from..
17/07/202317:05GLOBE4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial..
10/07/202320:30PRNUSAstellas and 4D Molecular Therapeutics (4DMT) Enter into..
07/06/202317:10GLOBE4DMT Presents Positive Interim Data from Aerosolized 4D-710..
01/06/202309:00GLOBE4D Molecular Therapeutics to Participate in Upcoming..

Seu Histórico Recente